Mara Goldstein
Stock Analyst at Mizuho
(2.60)
# 2,204
Out of 4,761 analysts
74
Total ratings
41.82%
Success rate
5.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $7 → $9 | $5.68 | +58.45% | 6 | Dec 19, 2024 | |
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $8.25 | +287.88% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $11.07 | +279.40% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $15.74 | +217.66% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $16.38 | +174.73% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $72.11 | +6.78% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.41 | +396.45% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.42 | +463.38% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.48 | +2,398.96% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $5.78 | +419.03% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.93 | +543.64% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $4.19 | -16.47% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.27 | +4,319.89% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $1.76 | +1,036.36% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $89.50 | +45.25% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $0.78 | +156.41% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.95 | +515.38% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.56 | +1,508.58% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $50.26 | -60.21% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.59 | +628.38% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.46 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.06 | +176.68% | 1 | Oct 12, 2017 |
Verastem
Dec 19, 2024
Maintains: Outperform
Price Target: $7 → $9
Current: $5.68
Upside: +58.45%
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $8.25
Upside: +287.88%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $11.07
Upside: +279.40%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $15.74
Upside: +217.66%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $16.38
Upside: +174.73%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $72.11
Upside: +6.78%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.41
Upside: +396.45%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.42
Upside: +463.38%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.48
Upside: +2,398.96%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $5.78
Upside: +419.03%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.93
Upside: +543.64%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $4.19
Upside: -16.47%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.27
Upside: +4,319.89%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.76
Upside: +1,036.36%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $89.50
Upside: +45.25%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $0.78
Upside: +156.41%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.95
Upside: +515.38%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.56
Upside: +1,508.58%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $50.26
Upside: -60.21%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.59
Upside: +628.38%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $22.46
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.06
Upside: +176.68%